Updated:
Centauri Therapeutics Limited
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology. The company uses its proprietary Alphamer technology to treat...
Centauri Therapeutics Limited
Centauri Therapeutics is an immunotherapy company focused on infectious diseases and oncology. The company uses its proprietary Alphamer technology to treat life-threatening diseases. Centauri has received funding from various sources, including the AMR Action Fund and CARB-X, to support the progression of its lead clinical candidate.
General information
Firm type
other
Location
Region
Europe
Country
United Kingdom
City
Alderley Park, Cheshire
Corporate office
Alderley Park, Nether Alderley, Cheshire SK10 4TG, United Kingdom
Principals
Jennifer Schneider
Team Member (PhD, MPH)
Helen Bright
Team Member (PhD, FRSM)
Debra Barker
Team Member (MD, MSc)
Samantha Macro
Team Member (PhD, MCA, MBA)
Hassan Al-Bewani
Team Member (PhD)
Antonia Atkinson
Team Member
Jessica Boyle
Team Member (PhD, MBA)
Matthew Bushdyhan
Team Member (MRes)
David Chapman
Team Member (PhD)
Zenobia D’Costa
Team Member (PhD)
Iman Hassanally
Strategy and Corporate Development Manager
Daniel Hynes
Team Member (BSc)
Adam Johnson
Team Member (PhD)
Lydia Jones
Team Member (PhD)
Khushi Khare
Team Member
Jaya Saini
Team Member (PhD)
Sector focus
Frequently asked questions
Who runs investment decisions at Centauri Therapeutics?
The company's team page lists senior scientists and a strategy manager, but Centauri has not publicly named a CEO, CIO, or managing principal. Investment decisions appear to rest with the listed leadership, including PhD-level researchers and the Strategy and Corporate Development Manager Iman Hassanally (per firm website).
How does Centauri Therapeutics source its funding?
The firm raises capital through venture rounds and non-dilutive grants. In February 2026, it extended its Series A to £30M with a £6M investment from the AMR Action Fund. It also receives grant funding from CARB-X, including a $5.1M award in July 2025 (per firm press releases).
What is Centauri's Alphamer® technology, and how is it different?
Alphamer® is a proprietary platform that redirects naturally existing antibodies in the body to target specific pathogens or cancer cells. Unlike traditional antibody engineering that creates new antibodies, Alphamer® leverages the patient's own immune system, potentially enabling faster and broader therapeutic application (per firm website).
Which sectors does Centauri explicitly avoid?
Centauri's public focus is limited to infectious diseases and oncology. The firm has not disclosed any sectors it explicitly avoids, but based on its pipeline and press releases, it does not appear active in areas such as gene therapy, rare diseases, or medical devices.
Is Centauri Therapeutics structured as a family office or asset manager?
No. Centauri appears to be an operating biotechnology company, not a family office or asset manager. It develops its own drug candidates and raises structured venture financing, similar to other early-stage biotech firms.
What regulatory milestones has Centauri achieved?
Centauri's lead candidate CTX-187 received FDA Qualified Infectious Disease Product (QIDP) designation in March 2026, which provides expedited development and regulatory pathways (per firm press release, March 2026).
What is the relationship between Centauri Therapeutics and the AMR Action Fund?
The AMR Action Fund invested £6M in Centauri's Series A extension closed in February 2026, making it a strategic investor. The Fund focuses on combating antimicrobial resistance and likely provides both capital and industry expertise (per firm press release, February 2026).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: